Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US.
Praveen ThokalaMatt StevensonVarun M KumarShijie RenAlexandra G EllisRichard H ChapmanPublished in: Cost effectiveness and resource allocation : C/E (2020)
The estimated incremental cost-effectiveness of nusinersen from a US health care sector perspective exceeded traditional cost-effectiveness thresholds. Cost-effectiveness was dependent on assumptions made regarding survival, costs, utilities, and whether the motor function milestones were sustained over lifetime. Given the relatively short-term effectiveness data available for the treatment, a registry to collect long-term data of infantile-onset SMA patients is recommended.